Subscribe to BioWorld™ news services
Bridge Biotherapeutics Inc. recently reported data for BBT-209, an endogenous G protein-coupled receptor 19 (GPCR19) agonist under development for the treatment of idiopathic pulmonary fibrosis (IPF).